Leveraging AI and RNA to Fight Rare Diseases

Along the Road to 50 States, Dr. Martin Akerman, Co-Founder and CTO at Envisagenics, talks to Nigel about the company's approach of combining AI technology and RNA to fight rare diseases and improve patients' lives around the world.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.


Envisagenics is an Artificial Intelligence-driven, biotechnology company that focuses on the discovery of novel RNA splicing events that cause cancer and other genetic diseases. Its principal technology is the SpliceCore® discovery platform. The platform re-envisions the human genome with a validated exon-centric approach, combined with machine learning algorithms and high-performance computing. It is up to 250 times more likely to discover novel targets than gene-centric discovery tools. Using innovative technology and RNA analysis expertise, Envisagenics accelerates the development of highly specific therapeutics that modulate RNA splicing events that drive pathogenesis of oncology, neurodegenerative, and metabolic disorders.

Envisagenics is a minority- and woman-led company that partners with biopharmaceutical companies and academic institutions to advance their drug discovery capabilities using its AI/ML platform. Envisagenics also has its own internally developed RNA therapeutic programs. For more information, please visit www.envisagenics.com. Follow us on social media: Twitter | LinkedIn | YouTube